Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]
Vir Biotechnology to Participate in Upcoming Investor Conferences
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.